Business Context and Reporting Period
Pulsenmore Ltd., a foreign private issuer based in Israel, filed this Form 6-K on June 25, 2026. The filing reports the entry into a definitive securities purchase agreement with an institutional investor to raise capital through a private placement.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $7.5 million expected from the offering.
- Offering Structure: Sale of 1,562,500 pre-funded warrants and 1,562,500 ordinary warrants.
- Purchase Price: $4.7999 per pre-funded warrant and accompanying ordinary warrant.
- Placement Fees: 7.0% cash fee plus up to $50,000 for expense reimbursement.
- Use of Proceeds: Marketing, commercialization, working capital, and general corporate purposes.
- Debt and Liquidity: The filing text does not provide specific values for existing debt, cash flow, or liquidity positions outside of the new capital raise.
Material Changes and Transaction Terms
The primary material change is the dilution of existing shareholders and the influx of new capital. Key terms include:
- Pre-Funded Warrants: Exercise price of $0.0001; immediately exercisable; no expiration until exercised.
- Ordinary Warrants: Exercise price of $4.80; immediately exercisable; expire five years from issuance.
- Beneficial Ownership Limit: Exercise is capped if it would cause the holder to own more than 4.99% of outstanding ordinary shares.
- Registration Obligations: The Company must file a registration statement within 10 trading days and seek effectiveness within 30 days (or 60 days if under full review), or pay liquidated damages.
Restrictions and Covenants
- Market Standoff: The Company cannot issue new shares or equivalents for 30 days following the registration statement's effective date.
- Lock-Up Agreements: Officers and directors are locked up for 30 days following the effective date.
- Variable Rate Transaction Ban: Prohibited for six months following the effective date.
Guidance, Risks, and Contingencies
The filing does not provide updated financial guidance or management commentary on operational performance. Key risks and contingencies identified include:
- Registration Risk: Failure to meet SEC filing or effectiveness deadlines triggers liquidated damages.
- Regulatory Compliance: Securities were sold under Section 4(a)(2) and Rule 506(b) exemptions; resale is restricted until a registration statement is effective.
- Dilution: The issuance of warrants will increase the number of outstanding shares upon exercise.
Investor Verification Checklist
- Verify the closing date of the offering (expected June 26, 2026) and confirmation of fund receipt.
- Confirm the filing and effectiveness status of the registration statement for the resale of warrant shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific liquidated damages clauses.
- Assess the impact of the 4.99% beneficial ownership limitation on the investor's ability to exercise warrants.
- Monitor the Company's use of proceeds against stated marketing and commercialization goals.